Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

GW Pharma to raise quarter of a billion dollars from US investors

It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.
GW Pharma to raise quarter of a billion dollars from US investors
American investors have been tapped for cash.

The UK’s GW Pharmaceuticals PLC (LON:GWP, NASDAQ:GWPH), a world leader in cannabis-based medicines, has outlined plans to raise US$252mln from US investors.

It is doing so via the issue of American Depositary Shares that will be listed on NASDAQ.

The stock is being offer at US$90, a modest discount to last night’s closing price of US$97.

The company said it will file next year for regulatory approval in the US for Epidiolex, used to treat severe epilepsy in children, after what were described as “stellar” late stage clinical trial results.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

man on a ventilator
January 24 2018
The share price, 280p a year ago, has tracked the progress the firm has made in the clinic with its lead product Traumakine
couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
little girl sneezing in a field
Mon
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use